Opioids in Cancer Pain Management: A Double-Edged Sword of Relief and Risk

Opioids are indispensable for managing cancer-related pain but carry risks such as immunosuppression, increased susceptibility to infections, and potential tumour progression. Balancing effective pain relief with these risks remains a critical challenge. This review examines the dual role of opioids in cancer pain management, highlighting their benefits, risks, and ethical implications while exploring strategies to mitigate adverse effects. Through a comprehensive literature review, we analysed mechanisms of opioid-induced immunosuppression, infection risks, tumour progression, and ethical prescribing practices. Additionally, strategies such as multimodal analgesia, opioid rotation, and personalised medicine were evaluated. Findings indicate that while opioids effectively alleviate cancer pain, they may suppress immune function, elevate infection risks, and potentially promote tumour progression. Mitigation strategies, including multimodal approaches, immunomodulatory interventions, and adherence to ethical principles (beneficence, non-maleficence, autonomy, and justice), are essential for safe opioid use. In conclusion, opioids remain vital for cancer pain management but require judicious application to minimise risks. Future research should prioritise non-opioid alternatives and immunomodulatory therapies to enhance patient outcomes.